Researchers compared the new-look drug coated balloon with an uncoated balloon, publishing their findings in JACC: Cardiovascular Interventions.

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why.

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care. 

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

The Smith Center for Outcomes Research in Cardiology examined real-world data from more than 700,000 CMS patients. The group's findings were presented during TCT 2021. 

Researchers reported at TCT 2021 that survival was 100% after 30 days.

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years.